secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022277
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B
--------------------------------------------------------------------------------

- Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.
- R&D expense $1.2M (down 56% YoY) due to grant funding; G&A $2.5M (up 25% YoY) on commercial readiness.
- DARE to PLAY Sildenafil Cream on track for initial Rx fulfillment Dec 2025 via 503B compounding (near-term revenue).
- Positive DSMB recommendation for Ovaprene Phase 3 study; enrollment continues.
- Received $6M (Jul) and $4M (Oct) grant installments for DARE-LARC1; $3.6M expected for DARE-NHC in Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/0001493152-25-022277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer